JW (Cayman) Therapeutics Co. Ltd

SEHK:2126 Stock Report

Market Cap: HK$517.9m

JW (Cayman) Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Min Liu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper

Nov 12
Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper

JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch

Sep 25
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch

A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb

May 10
A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb

Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

May 03
Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Feb 03
JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

CEO

Min Liu (51 yo)

less than a year

Tenure

Mr. Min Liu has been Chief Executive Officer and Executive Director of JW (Cayman) Therapeutics Co. Ltd. since July 31, 2024. He serves as the Chief Commercial Officer at Innovent Biologics Inc. Mr. Liu is...

Leadership Team

NamePositionTenureCompensationOwnership
Yiping Li
Co-Founder & Interim Chairmanless than a yearCN¥20.98m5.45%
HK$ 28.2m
Min Liu
CEO & Executive Directorless than a yearno datano data
Cao Xiaoping
Senior Vice President of Tech Operations2.4yrsno datano data
Shaun Paul Cordoba
Senior VP & Chief Scientific Officer2.9yrsno datano data
Raymond J. Hage
Senior Vice President of Corporate Development2.9yrsno datano data
Mark J. Gilbert
Senior Advisor & Acting Chief Medical Officerno datano datano data
Qiang Ma
Senior VP & Chief Commercial Officerno datano datano data
Yun Qin
Senior Vice President of Clinical Sciences & Medical Servicesno datano datano data
Su Yang
Senior Vice President Of Clinical Research & PMOno datano datano data
Ka Man Ng
Company Secretary3yrsno datano data

2.9yrs

Average Tenure

46yo

Average Age

Experienced Management: 2126's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yiping Li
Co-Founder & Interim Chairmanless than a yearCN¥20.98m5.45%
HK$ 28.2m
Min Liu
CEO & Executive Directorless than a yearno datano data
Jiuyun Yu
Independent Non-Executive Director1.8yrsCN¥276.00kno data
Peng Kuan Chan
Independent Non-Executive Directorless than a yearno datano data
Cheng Liu
Non-Executive Director4.5yrsCN¥331.00k1.42%
HK$ 7.4m
Kin-Cheong Ho
Independent Non-Executive Director4.2yrsCN¥224.00kno data
Sungwon Song
Non-Executive Director1.3yrsno datano data
Xing Gao
Non-Executive Director4.6yrsno datano data

1.5yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 2126's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JW (Cayman) Therapeutics Co. Ltd is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
Tony RenCLSA